T-cell immunogenicity and biomarker profiling in advanced melanoma patients receiving the personalized vaccine EVX-01 in combination with pembrolizumab

AI-designed cancer vaccines: antigens from the dark genome are promising cancer vaccine targets

Advancing Vaccine Development through Precise AI-driven Prediction of Protective Antigens.

Phase 2 study of AI-designed personalized neoantigen cancer vaccine, EVX-01, in combination with pembrolizumab in advanced melanoma

Immunogenicity of an AI-designed personalized neoantigen vaccine, EVX-01, in combination with anti-PD1 therapy in patients with metastatic melanoma